Natera raised its 2026 revenue guidance after reporting a 39% year-over-year jump in Q1 revenue driven by growth in clinical oncology testing and women’s health volumes. The company reset its full-year outlook to $2.74 billion–$2.82 billion, citing strong adoption of its Fetal Focus offering and sustained momentum in oncology minimal residual disease testing. Natera said clinical MRD volumes were on track for a one-million-test annual run rate, and it highlighted trial and clinical integration inputs, including the Flatiron Health OncoEMR linkage and expanded commercial footprint. The company also noted volume growth in core indications and said it increased the average selling price for Signatera from $1,225 to $1,250 in the quarter. Executives tied revenue growth to adoption and to test performance use cases, including studies that could support de-escalation and avoidance of invasive procedures in select settings. Management also referenced a target ASP trajectory toward $2,000, which it said would materially increase revenue at current run rates. For liquid biopsy competitors and payor negotiations, the guidance reset signals continuing market pull for molecular residual disease and women’s health genomics—especially when volume and reimbursement dynamics improve together.